Xtacy Therapeutics Corp. (TSE:XTCY) has released an update.
Xtacy Therapeutics Corp. has announced a strategic move to settle debts by issuing common shares, alongside exciting developments in their investees’ research into psychedelics and nutraceuticals for health and wellness. The company is issuing over 3 million shares to alleviate CA$180,000 of debt, aiming to strengthen their financial standing. Additionally, Xtacy’s partners are pioneering in the psychedelic research field and are set to launch an educational site on medicinal mushrooms and cannabinoids.
For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.
